Sight Sciences, Inc. (SGHT) Dividend History

Company News

• Dry Eye Treatment Devices Market Poised to Attain Valuation of US$ 898.78 Million By 2033 | Pharmacological Synergy Driving Demand for Advanced Dry Eye Treatment Devices Says Astute Analytica

  The global dry eye treatment devices market is expected to reach $898.78 million by 2033, driven by the increasing prevalence of dry eye disease and the development of innovative treatment options. The market is seeing a shift towards more sophisticated devices that offer targeted therapies, such as the LipiFlow System and iLux Device for treating meibomian gland dysfunction, and the trueTear intranasal neurostimulation device for stimulating tear production.

  GlobeNewswire Inc.

  Featured Companies: JNJ
• Sight Sciences to Report Second Quarter Financial Results on August 1, 2024 - GlobeNewswire

  Sight Sciences, Inc. (Nasdaq: SGHT) announced that it will report its financial results for the second quarter of 2024 on August 1, 2024. The company will host a conference call to discuss the results.

  GlobeNewswire Inc.
• Sight Sciences CFO Alison Bauerlein sells over $65k in company stock By Investing.com - Investing.com

  Sight Sciences CFO Alison Bauerlein sold over $65,000 worth of company stock to cover tax liabilities from vesting of restricted stock units. The company has reported positive developments in its trials and modest revenue growth, but also faces challenges with profitability.

  Investing.com
• Sight Sciences Announces the Release of its First Sustainability Report

  The Sustainability Report provides data for 2021 through 2023 on the Company’s environmental, social, and governance initiatives The Sustainability Report provides data for 2021 through 2023 on the Company’s environmental, social, and governance initiatives

  GlobeNewswire Inc.
• Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis

  Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve. Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and symptoms of dry eye disease through month twelve.

  GlobeNewswire Inc.